Intellia Therapeutics (NTLA) Faces A Fresh Valuation Test After Phase 3 Enrollment Wraps

Simply Wall St.11-18 18:08

Intellia Therapeutics (NTLA) has just wrapped enrollment in MAGNITUDE-2, its Phase 3 trial of CRISPR therapy nex-z for hereditary transthyretin amyloidosis with polyneuropathy, drawing fresh attention...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment